Publications by authors named "Jakub Trefler"

Claim this Profile
L
Lower total serum Immunoglobulin G is associated with impaired patient-reported health-related quality of life in systemic sclerosis: a prospective cross-sectional study.
Jakub Trefler, Anna Pasierb, Lidia Lech, Katarzyna Życińska

Rheumatol Int· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations of serum CA 15-3 with interstitial lung disease, PM/Scl100 antibodies and other disease characteristics in systemic sclerosis.
Jakub Trefler, Anna Pasierb, Lidia Lech, Katarzyna Życińska

Sci Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.
Mark G Lebwohl, John Y Koo, Janusz Jaworski, Jakub Trefler, Stefan Daniluk

Adv Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.
Gerd Burmester, Jakub Trefler, Artur Racewicz, Janusz Jaworski, Agnieszka Zielińska

Clin Drug Investig· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study.
David M Pariser, Mark G Lebwohl, Janusz Jaworski, Jakub Trefler, Stefan Daniluk

Dermatol Ther (Heidelb)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study.
Gerd Burmester, Piotr Adrian Klimiuk, Jakub Trefler, Janusz Jaworski, SungHyun Kim

Expert Rev Clin Immunol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.
Mark G Lebwohl, John Y Koo, Janusz Jaworski, Jakub Trefler, Stefan Daniluk

Adv Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.
Josef S Smolen, Jakub Trefler, Artur Racewicz, Janusz Jaworski, Agnieszka Zielińska

RMD Open· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
Kim A Papp, Mark G Lebwohl, Diamant Thaçi, Janusz Jaworski, Bartlomiej Kwiek, Jakub Trefler

BioDrugs· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis.
Daniel E Furst, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Jakub Trefler

Rheumatology (Oxford)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial.
Rene Westhovens, Piotr Wiland, Marek Zawadzki, Delina Ivanova, Alfredo Berrocal Kasay, Jakub Trefler

Rheumatology (Oxford)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.
Jonathan Kay, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Jakub Trefler

Arthritis Res Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Influence of genetic factors on development and severity of rheumatoid arthritis--part I].
Jakub Trefler, Agnieszka Paradowska-Gorycka, Ewa Matyska-Piekarska, Maria Rell-Bakalarska, Bozena Wojciechowska

Pol Merkur Lekarski· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Influence of genetic factors on development and severity of rheumatoid arthritis--part II].
Jakub Trefler, Agnieszka Paradowska-Gorycka, Jan K Łacki

Pol Merkur Lekarski· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients?
Izabela Korczowska, Anna Olewicz-Gawlik, Jakub Trefler, Paweł Hrycaj, Jan Krzysztof Łacki

Clin Rheumatol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Amyloidosis--life threatening complication in rheumatoid arthritis patients].
Jakub Trefler, Ewa Matyska-Piekarska, Teresa Wagner, Jan K Łacki

Wiad Lek· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Cyclophosphamide in the therapy of rheumatoid arthritis and its complications].
Jakub Trefler, Ewa Matyska-Piekarska, Jan K Łacki

Pol Merkur Lekarski· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis